Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland
Advertisement

Novartis profits down in first quarter

Share this article

13:55 CEST+02:00

Swiss pharmaceutical giant Novartis saw its first quarter net profit fall 4.0 percent to $2.82 billion, the company announced on Tuesday.

 

Swiss pharmaceutical giant Novartis saw its first quarter net profit fall 4.0 percent to $2.82 billion, the company announced on Tuesday.

The fall was mainly due to financing costs related to its purchase of eyecare giant Alcon, the company said.

One-off costs associated with merging Alcon over the next three years are expected to reach $600 million. The sum includes severance, retention and relocation charges, said the group.

The integration of Alcon into Novartis' IT platform alone is estimated to cost around $350 million, it added in its earnings statement.

Meanwhile, sales were up 16 percent in the first three months of the year at $14 billion, as the group benefitted from reporting in the US dollar, which has weakened against most key currencies.

The currency impact translated to a 2.0 percent boost on sales, noted the group.

Novartis chief executive Joseph Jimenez expressed satisfaction at the results, saying that "contributions from all businesses led to a good start in 2011."

The Basel-based group confirmed its targets for the year, saying that it expects sales to "grow around the double-digit mark in 2011."

It added that if exchange rates in March were to prevail for the whole year, there would be a positive impact of 3.0 percent on sales, and a negative impact of -2.0 percent on its operating income for the full year.

 

Get notified about breaking news on The Local

Share this article

Advertisement
Advertisement
Advertisement
Jobs
Click here to start your job search
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement